Despite excitement about the extended spectrum of potential targets in personalized immunotherapy, there is no experience or consensus on the path to their successful clinical application. Major questions remain, such as whether clinical responses to cytokine therapy, T cell transfer, and checkpoint blockade are primarily mediated by m-peptide-specific reactivity, whether m-peptides can be effectively used as vaccines, and which m-peptides are most potently recognized. These and other technological, immunological and translational questions will be explored during a 1-day Workshop on Personalized Cancer Immunotherapy by the Society for Immunotherapy of Cancer, directly before the Annual Meeting, on November 7, 2013 at the National Harbor, MD near Washington, DC.Authors: Willem W. Overwijk, Ena Wang, Francesco M. Marincola, Hans-Georg Rammensee and Nicholas P. Restifo for the Organizing Committee of the 2013 SITC Workshop on Personalized ImmunotherapyPublished as a review in the Journal for ImmunoTherapy of Cancer (2013) 1:11.#SITCPublication